ABBREVIATIONS
RASSF1ARAS association domain family protein 1A RARβ retionic acid receptor β MSP methylation specific PCR ERα estrogen receptor α PRB progesterone receptor B
ACKNOWLEDGEMENTSWe are grateful to Department of Biotechnology, India, for providing the financial support to conduct this study. S.M. is grateful to University Grant Commission for award of Junior Research Fellowship. The authors thank Dr. Cecile Rochette Egly for the kind gift of RARβ monoclonal antibody.
Research PaperDetection of RASSF1A and RARβ Hypermethylation in Serum DNA from Breast Cancer Patients
ABSTRACTBreast cancer is fast emerging as the leading cancer amongst females, especially in young females in metropolitan cities in India. The epigenetic alterations involved in the onset and progression of breast cancer may serve as biomarkers for early detection and prognosis of the disease. Furthermore, using body fluids such as serum offers a noninvasive method to procure multiple samples for such analyses. In this study, we examined methylation status of two normally unmethylated but biologically significant cancer genes, RAS association domain family protein 1A (RASSF1A) and retionic acid receptor β (RARβ) by methylation specific PCR (MSP) in invasive ductal carcinomas of the breast and paired serum DNA. RASSF1A was found to be methylated in 17 of 20 (85%) breast tumors; while sera from 15 of 20 (75%) of the patients showed concordant methylated RASSF1A, with a sensitivity of 88%. RARβ was methylated in 2/20 (10%) breast tumors. A gene unmethylated in the tumor DNA was always found to be unmethylated in the matched serum DNA for both RASSF1A and RARβ genes; hence specificity was 100%. Immunohistochemical analysis of RARβ protein in 15 breast carcinoma patients harboring unmethylated RARβ in tumors and serum DNA showed the expression of RARβ protein in tumors and paired normal breast tissues, confirming the MSP findings, suggesting that RARβ promoter is functional in these cases. This study underscores the potential utility of DNA methylation based screening of serum, a readily accessible body fluid, as a surrogate marker for early detection of breast cancer.